European Union - English - EMA (European Medicines Agency)

galderma international - brimonidine tartrate - skin diseases - other dermatological preparations - mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.

Canada - English - Health Canada

galderma canada inc - brimonidine (brimonidine tartrate) - gel - 0.33% - brimonidine (brimonidine tartrate) 0.33% - misc. skin and mucous membrane agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

galderma (uk - brimonidine tartrate - gel - 3mg/1gram

Singapore - English - HSA (Health Sciences Authority)

galderma singapore private limited - brimonidine tartrate 5mg/g eqv brimonidine - gel - brimonidine tartrate 5mg/g eqv brimonidine 3.3mg/g

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

laboratoires galderma z.i. montdesir - brimonidine (brimonidine tartrate) - gel - 3,3mg/g

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

galderma, france - brimonidine tartrate - gel - 3 mg/g

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

galderma - brimonidine tartrate - gel - 3 mg/g

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

galderma, france - brimonidine tartrate - gel - 3 mg/g

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - brimonidine tartrate 5 mg/g equivalent to 3.3mg/g brimonidine;   - topical gel - 3.3 mg/g - active: brimonidine tartrate 5 mg/g equivalent to 3.3mg/g brimonidine   excipient: carbomer 974 glycerol methyl hydroxybenzoate phenoxyethanol propylene glycol sodium hydroxide titanium dioxide - mirvaso is indicated for the treatment of facial erythema of rosacea in adult patients